These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8274618)

  • 1. Therapy with antibody to tumor necrosis factor in sepsis.
    Pennington JE
    Clin Infect Dis; 1993 Nov; 17 Suppl 2():S515-9. PubMed ID: 8274618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group.
    Fisher CJ; Opal SM; Dhainaut JF; Stephens S; Zimmerman JL; Nightingale P; Harris SJ; Schein RM; Panacek EA; Vincent JL
    Crit Care Med; 1993 Mar; 21(3):318-27. PubMed ID: 8440099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies.
    Wherry JC; Pennington JE; Wenzel RP
    Crit Care Med; 1993 Oct; 21(10 Suppl):S436-40. PubMed ID: 8403981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock.
    Silva AT; Bayston KF; Cohen J
    J Infect Dis; 1990 Aug; 162(2):421-7. PubMed ID: 2373872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody.
    Hinshaw LB; Emerson TE; Taylor FB; Chang AC; Duerr M; Peer GT; Flournoy DJ; White GL; Kosanke SD; Murray CK
    J Trauma; 1992 Oct; 33(4):568-73. PubMed ID: 1433404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis.
    Opal SM; Cross AS; Sadoff JC; Collins HH; Kelly NM; Victor GH; Palardy JE; Bodmer MW
    J Clin Invest; 1991 Sep; 88(3):885-90. PubMed ID: 1885775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of septic shock with antibodies to tumour necrosis factor.
    Cohen J; Exley AR
    Schweiz Med Wochenschr; 1993 Mar; 123(11):492-6. PubMed ID: 8475356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical review of anti-tumor necrosis factor monoclonal antibodies.
    Bodmer M; Fournel MA; Hinshaw LB
    Crit Care Med; 1993 Oct; 21(10 Suppl):S441-6. PubMed ID: 8403982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
    Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
    JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Search for effective immunomodulating strategies against sepsis.
    Vincent JL
    Lancet; 1998 Mar; 351(9107):922-3. PubMed ID: 9734931
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of anti-TNF-alpha treatment in an antibiotic treated murine model of shock due to Streptococcus pyogenes.
    Martin RA; Silva AT; Cohen J
    FEMS Microbiol Lett; 1993 Jun; 110(2):175-8. PubMed ID: 8349091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha).
    Hinshaw LB; Tekamp-Olson P; Chang AC; Lee PA; Taylor FB; Murray CK; Peer GT; Emerson TE; Passey RB; Kuo GC
    Circ Shock; 1990 Mar; 30(3):279-92. PubMed ID: 2178801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapies for sepsis. Emerging therapies for sepsis and septic shock.
    Abraham E
    West J Med; 1997 Mar; 166(3):195-200. PubMed ID: 9143195
    [No Abstract]   [Full Text] [Related]  

  • 15. Current prospects for the treatment of clinical sepsis.
    Suffredini AF
    Crit Care Med; 1994 Jul; 22(7):S12-8. PubMed ID: 8026188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of combination immunotherapy in experimental Pseudomonas sepsis.
    Cross AS; Opal SM; Palardy JE; Bodmer MW; Sadoff JC
    J Infect Dis; 1993 Jan; 167(1):112-8. PubMed ID: 8418157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytokines and septic shock. New perspectives on its treatment].
    Zamora Madaria E
    An Med Interna; 1993 Dec; 10(12):573-5. PubMed ID: 8049320
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxemic baboon model.
    Emerson TE; Lindsey DC; Jesmok GJ; Duerr ML; Fournel MA
    Circ Shock; 1992 Oct; 38(2):75-84. PubMed ID: 1423924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of prophylactic and therapeutic use of a murine anti-tumor necrosis factor monoclonal antibody in Escherichia coli sepsis in the rabbit.
    Stack AM; Saladino RA; Thompson C; Sattler F; Weiner DL; Parsonnet J; Nariuchi H; Siber GR; Fleisher GR
    Crit Care Med; 1995 Sep; 23(9):1512-8. PubMed ID: 7664553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.
    Abraham E; Anzueto A; Gutierrez G; Tessler S; San Pedro G; Wunderink R; Dal Nogare A; Nasraway S; Berman S; Cooney R; Levy H; Baughman R; Rumbak M; Light RB; Poole L; Allred R; Constant J; Pennington J; Porter S
    Lancet; 1998 Mar; 351(9107):929-33. PubMed ID: 9734938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.